![Matthew Wiggetts](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthew Wiggetts
Director/Miembro de la Junta en Amryt Pharma Holdings Ltd. .
Perfil
Matthew Hammond Wiggetts has worked as a Secretary & Director for Amryt Pharma Holdings Ltd.
since 2023.
Cargos activos de Matthew Wiggetts
Empresas | Cargo | Inicio |
---|---|---|
Amryt Pharma Holdings Ltd.
![]() Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | 26/05/2023 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Amryt Pharma Holdings Ltd.
![]() Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Matthew Wiggetts